<DOC>
	<DOCNO>NCT01721213</DOCNO>
	<brief_summary>As part European post-marketing commitment , GSK conduct survey physician ' patient ' understanding significant risk associate Trobalt™ ( retigabine ) , describe Patient Information Leaflet ( PIL ) Physician 's Guide . The goal survey evaluate effectiveness educational plan specify European Risk Management Plan ( RMP ) . The objective study assess patient ' prescribers ' understand knowledge significant risk associate Trobalt™ use evaluate survey instrument . This cross sectional survey : 1 . 250 patient recruit across follow country ( United Kingdom , Sweden , Denmark , Switzerland , Spain , Slovakia Norway ) 100 patient Germany currently use fill prescription Trobalt™ least last 3 month . 2 . 200 neurologist prescribe anti-epileptic drug ( AED ) least last 3 month , list letter contain Physician 's Guide Trobalt™ distribute across follow country ( United Kingdom , Sweden , Denmark , Switzerland , Spain , Slovakia Norway ) . At least 75 neurologist prescribe Trobalt™ . The survey also aim include 100 neurologist Germany approximately 50 prescribed Trobalt™ . Patients eligible survey ask take survey online via telephone interview latter prefer . Neurologists invite take survey online . The selected country first five country launch Trobalt™ ( Germany , Denmark , United Kingdom , Switzerland Sweden ) additional three country launch 2011 , relatively high rate uptake Trobalt™ ( Spain , Slovakia Norway ) . The selection country include Switzerland , part European Union . However , key message regard risk Trobalt™ alignment . The rationale survey first five country launch issue identify country regard effectiveness Physician 's Guide PIL communicate risk Trobalt™ address soon possible , key message revise timely manner . In addition , country likely provide great number neurologist experience prescribe Trobalt™ , patient . The primary outcome survey proportion patients/neurologists provide correct response series question concern significant risk associate Trobalt™ . The risk evaluate described Trobalt™ PIL Physician 's Guide .</brief_summary>
	<brief_title>Trobalt™ Products Risk Survey</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Patients require meet following inclusion criterion : Use Trobalt™ : current use least one prescription fill within previous three month . 18 year age old . Willing take online survey survey administer via telephone interview . Physicians required meet follow inclusion criterion : Must prescribe AED least last 3 month Must list Physician 's Guide Trobalt™ distribute . Patients meet follow criterion eligible take survey : Unable understand complete survey internet phone . Currently employee GSK UBC . Physicians meet follow criterion eligible take survey : Currently employee GSK UBC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>survey</keyword>
	<keyword>retigabine</keyword>
	<keyword>patient information leaflet</keyword>
	<keyword>physician 's guide</keyword>
	<keyword>Trobalt™</keyword>
</DOC>